NATALIZUMAB Side Effects

7019727-0 | Progressive Multifocal Leukoencephalopathy
on Sep 22, 2010 Female patient from POLAND , 33 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with METHYLPREDISILONE (View Methylpredisilone Review and Methylpredisilone Label ). Patient was hospitalized.

7005166-5 | Angioedema, Pruritus, Pruritus Genital, Urticaria
Patient was taking Natalizumab (View Usage). Patient had the following side effects: angioedema, pruritus, pruritus genital, urticaria on Sep 20, 2010 from UNITED STATES Additional patient health information: Female patient , 54 years of age, weighting 128.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: 300 Mg Ud Iv. Patient was hospitalized.

6997778-X | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Sep 16, 2010 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: POLAND , 33 years of age, After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with METHYLPREDISILONE (View Methylpredisilone Review and Methylpredisilone Label ). Patient was hospitalized.

6997768-7 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Sep 08, 2010 Female patient from UNITED STATES , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.


6984169-0 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Aug 31, 2010 Female patient from UNITED STATES , 35 years of age, weighting 158.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), vaginitis bacterial and was treated with Natalizumab (View Usage). Patient had the following side effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), METRONIDAZOLE VAGINAL (View Metronidazole Vaginal Review and Metronidazole Vaginal Label ). Patient was hospitalized.

6977584-2 | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy on Sep 09, 2010 from POLAND Additional patient health information: Female patient , 33 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: . During the same period patient was treated with METHYLPREDISILONE (View Methylpredisilone Review and Methylpredisilone Label ). Patient was hospitalized.

6972022-8 | Malignant Melanoma
Adverse event was reported on Aug 31, 2010 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), osteoporosis (What is osteoporosis?) and. Location: ITALY , 38 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: malignant melanoma. During the same period patient was treated with CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ).

6907432-8 | Cholecystitis
on Jul 29, 2010 Female patient from AUSTRALIA , 50 years of age, weighting 121.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: cholecystitis. Natalizumab dosage: . During the same period patient was treated with IRBESARTAN (View Irbesartan Review and Irbesartan Label ), ERGOCALCIFEROL (View Ergocalciferol Review and Ergocalciferol Label ), LATANOPROST (Dose Unit:1.5) (View Latanoprost Review and Latanoprost Label ), LEVLEN 28 (View Levlen 28 Review and Levlen 28 Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6855222-7 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Jul 09, 2010 Female patient from UNITED STATES , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6811537-X | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy on Jun 23, 2010 from UNITED STATES Additional patient health information: Female patient , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6794196-4 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Jun 17, 2010 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and. Location: FRANCE , 45 years of age, weighting 125.7 lb, Patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMIN B6 (View Magnesium + Vitamin B6 Review and Magnesium + Vitamin B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6777901-2 | Aspartate Aminotransferase Increased, Blood Urea Abnormal, Malignant Melanoma, Red Blood Cell Count Decreased, Skin Graft
on Jun 15, 2010 Female patient from ITALY , 38 years of age, weighting 141.1 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), osteoporosis (What is osteoporosis?) and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: aspartate aminotransferase increased, blood urea abnormal, malignant melanoma, red blood cell count decreased, skin graft. Natalizumab dosage: . During the same period patient was treated with CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ).

6768280-5 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Jun 01, 2010 Female patient from GERMANY , 35 years of age, weighting 158.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), vaginitis bacterial and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), METRONIDAZOLE VAGINAL (View Metronidazole Vaginal Review and Metronidazole Vaginal Label ). Patient was hospitalized.

6705385-9 | Cholecystitis
Patient was taking Natalizumab (View Usage). Patient had the following side effects: cholecystitis on Apr 28, 2010 from AUSTRALIA Additional patient health information: Female patient , 50 years of age, weighting 121.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: . During the same period patient was treated with IRBESARTAN (View Irbesartan Review and Irbesartan Label ), ERGOCALCIFEROL (View Ergocalciferol Review and Ergocalciferol Label ), LATANOPROST (Dose Unit:1.5) (View Latanoprost Review and Latanoprost Label ), LEVLEN 28 (View Levlen 28 Review and Levlen 28 Label ). Patient was hospitalized.

6699576-3 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Apr 22, 2010 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Location: UNITED STATES , 43 years of age, weighting 165.3 lb, After Natalizumab was administered, patient had the following side effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6664816-3 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Mar 25, 2010 Female patient from UNITED STATES , 35 years of age, weighting 158.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), vaginitis bacterial and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), METRONIDAZOLE VAGINAL (View Metronidazole Vaginal Review and Metronidazole Vaginal Label ). Patient was hospitalized.

6609334-3 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
on Feb 19, 2010 Female patient from CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). Patient had the following side effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6609332-X | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy on Feb 19, 2010 from FRANCE Additional patient health information: Female patient , 45 years of age, weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and. Natalizumab dosage: . During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMIN B6 (View Magnesium + Vitamin B6 Review and Magnesium + Vitamin B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6557245-4 | Immune Reconstitution Syndrome, Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Jan 20, 2010 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Location: CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: immune reconstitution syndrome, progressive multifocal leukoencephalopathy. During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6519778-6 | Back Pain, Chest Pain, Myalgia
on Dec 28, 2009 Male patient from UNITED STATES , 52 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: back pain (What is back pain?), chest pain (What is chest pain?), myalgia. Natalizumab dosage: 300 Mg Other Iv.

6514394-4 | Progressive Multifocal Leukoencephalopathy
on Dec 16, 2009 Female patient from CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6476418-2 | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy on Nov 25, 2009 from CZECH REPUBLIC Additional patient health information: Female patient , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6449918-9 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Nov 13, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Location: CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, Patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL (View Metamizol Review and Metamizol Label ), PITOPHENONE (View Pitophenone Review and Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ). Patient was hospitalized.

6429659-4 | Progressive Multifocal Leukoencephalopathy
on Oct 30, 2009 Female patient from GERMANY , 35 years of age, weighting 158.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), vaginitis bacterial and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), METRONIDAZOLE VAGINAL (View Metronidazole Vaginal Review and Metronidazole Vaginal Label ). Patient was hospitalized.

6426044-6 | Progressive Multifocal Leukoencephalopathy
on Oct 30, 2009 Female patient from CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ), METAMIZOL + PITOPHENONE (View Metamizol + Pitophenone Review and Metamizol + Pitophenone Label ), THIOCOLCHICOSIDE (View Thiocolchicoside Review and Thiocolchicoside Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MONOCLONAL ANTIBODIES (View Monoclonal Antibodies Review and Monoclonal Antibodies Label ), TOPIRAMATE (View Topiramate Review and Topiramate Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6424683-X | Agitation, Anxiety, Eye Pruritus, Infusion Related Reaction, Nausea, Throat Irritation, Urticaria
Patient was taking Natalizumab (View Usage). Patient had the following side effects: agitation, anxiety (What is anxiety?), eye pruritus, infusion related reaction, nausea (What is nausea?), throat irritation, urticaria on Nov 02, 2009 from UNITED STATES Additional patient health information: Female patient , 50 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: 300 Mg Other Iv.

6420717-7 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Oct 26, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: GERMANY , 35 years of age, weighting 158.7 lb, After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with CITALOPRAM (View Citalopram Review and Citalopram Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ). Patient was hospitalized.

6412354-5 | Progressive Multifocal Leukoencephalopathy
on Oct 19, 2009 Female patient from CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ). Patient was hospitalized.

6410658-3 | Malignant Melanoma
on Oct 13, 2009 Female patient from ITALY , 38 years of age, weighting 141.1 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), osteoporosis (What is osteoporosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: malignant melanoma. Natalizumab dosage: . During the same period patient was treated with CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ).

6410641-8 | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy on Oct 19, 2009 from FRANCE Additional patient health information: Female patient , 45 years of age, weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and. Natalizumab dosage: . During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMIN B6 (View Magnesium + Vitamin B6 Review and Magnesium + Vitamin B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6402826-1 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Oct 12, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), migraine prophylaxis and. Location: CZECH REPUBLIC , 43 years of age, weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with TOPIRAMAT SANDOZ (View Topiramat Sandoz Review and Topiramat Sandoz Label ). Patient was hospitalized.

6370458-X | Lung Neoplasm Malignant
on Sep 18, 2009 Female patient from BELGIUM , 45 years of age, weighting 112.4 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: lung neoplasm malignant. Natalizumab dosage: . Patient was hospitalized.

6355743-X | Progressive Multifocal Leukoencephalopathy
on Sep 02, 2009 Female patient from FRANCE , 45 years of age, weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. Natalizumab dosage: . During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMIN B6 (View Magnesium + Vitamin B6 Review and Magnesium + Vitamin B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6340331-1 | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy on Aug 26, 2009 from FRANCE Additional patient health information: Female patient , 45 years of age, weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and. Natalizumab dosage: . During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMIN B6 (View Magnesium + Vitamin B6 Review and Magnesium + Vitamin B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6291264-0 | Urticaria
Adverse event was reported on Jul 28, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: 300mg, Every 4 Weeks, Iv) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , weighting 121.3 lb, Patient had the following side effects: urticaria.

6290723-4 | Urticaria
on Jul 22, 2009 Female patient from UNITED STATES , weighting 121.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: urticaria. Natalizumab dosage: 300mg Every 4 Weeks Iv.

6289292-4 | Pulmonary Embolism
on Jul 15, 2009 Female patient from SWEDEN , 49 years of age, was diagnosed with relapsing-remitting multiple sclerosis, micturition urgency, pain (What is pain?), muscle spasticity, depression (What is depression?) and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). Natalizumab dosage: . During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), TOLTERODINE TARTRATE (View Tolterodine Tartrate Review and Tolterodine Tartrate Label ), DICLOFENAC (View Diclofenac Review and Diclofenac Label ), BACLOFEN (View Baclofen Review and Baclofen Label ), ALVEDON FORTE (View Alvedon Forte Review and Alvedon Forte Label ), TRYPTIZOL (View Tryptizol Review and Tryptizol Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ).

6262225-2 | Transient Ischaemic Attack
Patient was taking Natalizumab (View Usage). Patient had the following side effects: transient ischaemic attack on Jul 07, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 54 years of age, weighting 180.8 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: . During the same period patient was treated with ATORVASTATIN CALCIUM (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), TOLTERODINE TARTRATE (View Tolterodine Tartrate Review and Tolterodine Tartrate Label ), GLICLAZIDE (View Gliclazide Review and Gliclazide Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized and became disabled.

6238404-7 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Jun 13, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: GERMANY , 35 years of age, weighting 158.7 lb, After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with CITALOPRAM (View Citalopram Review and Citalopram Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ). Patient was hospitalized.

6238392-3 | Anxiety
on Jun 11, 2009 Female patient from SPAIN , 35 years of age, weighting 132.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: anxiety (What is anxiety?). Natalizumab dosage: . During the same period patient was treated with TRANKIMAXIN (View Trankimaxin Review and Trankimaxin Label ). Patient was hospitalized.

6228209-5 | Anxiety
on Jun 04, 2009 Female patient from SPAIN , 35 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: anxiety (What is anxiety?). Natalizumab dosage: . During the same period patient was treated with BROMAZEPAM (View Bromazepam Review and Bromazepam Label ), FLUOXETINE HCL (View Fluoxetine Hcl Review and Fluoxetine Hcl Label ). Patient was hospitalized.

6228206-X | Progressive Multifocal Leukoencephalopathy
Patient was taking Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy on Jun 09, 2009 from FRANCE Additional patient health information: Female patient , 45 years of age, weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), affective disorder, pain (What is pain?), contraception and. Natalizumab dosage: . During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM + VITAMINE B6 (View Magnesium + Vitamine B6 Review and Magnesium + Vitamine B6 Label ), DIANTALVIC (View Diantalvic Review and Diantalvic Label ), LUTHERAN (View Lutheran Review and Lutheran Label ). Patient was hospitalized.

6207083-7 | Breast Cancer In Situ, Paget's Disease Of The Breast
Adverse event was reported on May 20, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: AUSTRALIA , 48 years of age, weighting 147.7 lb, Patient experienced the following unwanted or unexpected effects: breast cancer in situ, paget's disease of the breast. Patient was hospitalized.

6187417-2 | Mania
on Apr 27, 2009 Female patient from FRANCE , 37 years of age, weighting 165.3 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient had the following side effects: mania. Natalizumab dosage: . During the same period patient was treated with ALFUZOSINE (View Alfuzosine Review and Alfuzosine Label ), NIFLUMIC ACID (View Niflumic Acid Review and Niflumic Acid Label ), CEFPODOXIME PROXETIL (View Cefpodoxime Proxetil Review and Cefpodoxime Proxetil Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), SEGLOR (View Seglor Review and Seglor Label ), SOLU MEDROL? (View Solu-medrol? Review and Solu-medrol? Label ). Patient was hospitalized.

6085766-X | Malnutrition, Toxic Encephalopathy
on Feb 12, 2009 Female patient from UNITED STATES , 44 years of age, weighting 92.59 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), muscle spasticity, depression (What is depression?), neuralgia, tremor, fatigue and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: malnutrition, toxic encephalopathy. Natalizumab dosage: . During the same period patient was treated with BACLOFEN (View Baclofen Review and Baclofen Label ), EFFEXOR XR (View Effexor Xr Review and Effexor Xr Label ), WELLBUTRIN XL (View Wellbutrin Xl Review and Wellbutrin Xl Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), PROPANOLOL HCL (View Propanolol Hcl Review and Propanolol Hcl Label ), PROVIGIL (View Provigil Review and Provigil Label ), PRIMIDONE (View Primidone Review and Primidone Label ), BONIVA (View Boniva Review and Boniva Label ). Patient was hospitalized.

6051305-2 | Encephalopathy
Patient was taking Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: encephalopathy on Jan 16, 2009 from UNITED STATES Additional patient health information: Female patient , 44 years of age, weighting 92.59 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), muscle spasticity, depression (What is depression?), neuralgia, tremor, fatigue and. Natalizumab dosage: . During the same period patient was treated with BACLOFEN (View Baclofen Review and Baclofen Label ), EFFEXOR XR (View Effexor Xr Review and Effexor Xr Label ), WELLBUTRIN XL (View Wellbutrin Xl Review and Wellbutrin Xl Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), PROPANOLOL HCL (View Propanolol Hcl Review and Propanolol Hcl Label ), PROVIGIL (View Provigil Review and Provigil Label ), PRIMIDONE (View Primidone Review and Primidone Label ), BONIVA (View Boniva Review and Boniva Label ). Patient was hospitalized.

6051298-8 | Mania
Adverse event was reported on Jan 15, 2009 by a Female patient taking Natalizumab (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: FRANCE , 37 years of age, weighting 165.3 lb, Patient had the following side effects: mania. During the same period patient was treated with ALFUZOSINE (View Alfuzosine Review and Alfuzosine Label ), NIFLUMIC ACID (View Niflumic Acid Review and Niflumic Acid Label ), CEFPODOXIME PROXETIL (View Cefpodoxime Proxetil Review and Cefpodoxime Proxetil Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), SEGLOR (View Seglor Review and Seglor Label ). Patient was hospitalized.

6017750-6 | Haemoptysis, Lung Neoplasm Malignant
on Dec 16, 2008 Female patient from BELGIUM , 45 years of age, weighting 112.4 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). After Natalizumab was administered, patient had the following side effects: haemoptysis, lung neoplasm malignant. Natalizumab dosage: . Patient was hospitalized.

5648892-2 | Anaphylactic Reaction
on Mar 03, 2008 Male patient from UNITED STATES , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Natalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic reaction. Natalizumab dosage: 300mg Other Iv.

5623789-2 | Abortion Spontaneous, Memory Impairment
Patient was taking Natalizumab (View Usage). Patient had the following side effects: abortion spontaneous, memory impairment on Jan 25, 2008 from UNITED STATES Additional patient health information: Female patient , 29 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Natalizumab dosage: 300 Mg; Qm; Iv. During the same period patient was treated with NEXIUM (View Nexium Review and Nexium Label ), FOSAMAX (View Fosamax Review and Fosamax Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), VESICARE (View Vesicare Review and Vesicare Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), RESTORIL (View Restoril Review and Restoril Label ), MIDODRINE (View Midodrine Review and Midodrine Label ), BACLOFEN (View Baclofen Review and Baclofen Label ).